Dr. John Sampalis, CEO of JSS talks about the impact that changes in the global R&D landscape have had on JSS, the role technology is playing in running an efficient clinical trial program and the company’s next exciting move into the US.
John, what have been the main milestones of the company’s development since we last met you in 2013?
"At JSS, we are not just a pure academic CRO, although we nurture academic development, but we also serve industry at the same time."
Bob McLay, vice president and general manager of Sobi in Canada, discusses how innovation and collaboration with regulators and payers are helping Sobi to bring its medicines to Canadians suffering…
“If you are trying to be everything to everybody, you end up being nothing to no one”—Michael Gorenstein, CEO of The Cronos Group talks to PharmaBoardroom about his unusual career…
With already 20 percent of market share in the medical cannabis sector in Canada, MedReleaf is getting ready for the upcoming legalization of cannabis for recreational use. The company’s CEO…
Based on IQVIA’s pharma market rankings for 2020, we give a rundown of the global top 10, key companies, important trends, and where you can go to learn more. …
In conversation in the October edition of DIA’s Global Forum magazine, Canadian Agency for Drugs and Technologies in Health (CADTH) CEO Suzanne McGurn highlights how the work of HTA bodies…
Writing in the September edition of DIA’s Global Forum magazine, Dr Judith Glennie examines the specific steps that have been taken in the journey towards a National Pharmacare program in…
See our Cookie Privacy Policy Here